CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs.
$1.36+4.62%
报价 2026-11-06
市值
$4.3M
EV
$-13.4M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -96.0%
$1.02$33.70
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| CALCCalciMedica, Inc. | $4.3M | +4.6% | -90.4% | 0% | – | – | – | |
| PDSBPDS Biotechnology Corporation | $68.7M | +5.1% | +2700.0% | 0% | – | – | – | |
| MAIAMAIA Biotechnology, Inc. | $65.4M | +1.9% | – | – | – | – | – | |
| XLOXilio Therapeutics, Inc. | $56.7M | +1.4% | -12.2% | 0% | – | – | – | |
| RNXTRenovoRx, Inc. | $51M | -5.0% | +146.2% | 84.4% | – | – | – | |
| ATNMActinium Pharmaceuticals, Inc. | $45M | +10.0% | +12800.0% | 101.1% | 4.0x | 0.8x | – | |
| ELUTElutia Inc. | $37.1M | +11.5% | -36.5% | 59% | 0.7x | – | – | |
| TVRDTvardi Therapeutics, Inc. | $12.8M | +10.8% | -100.0% | 0% | – | – | – | |
| LTRNLantern Pharma Inc. | $8.5M | +6.7% | – | 0% | – | – | – | |
| 同行中位数 | – | – | +67.0% | 0% | 2.3x | 0.8x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。